@b2idigitalSep 1, 2026 · 0:39 · original sound - David Shapiro
Unicycive Therapeutics, Inc. (Nasdaq: UNCY) announced that Chief Executive Officer Shalabh Gupta, MD, M.D., will present at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, 2026, at 11 a.m. ET. A link to the live and archived webcast may be accessed on the Unicycive website under the Investors section, at Events and Presentations. Unicycive Therapeutics, Inc. is a B2i Digital Featured Company. See the company's in-depth profile at: https://b2idigital.com/unicycive The company's clinical-stage pipeline consists of two investigational treatments aimed at different conditions within kidney disease: • Lead investigational treatment oxylanthanum carbonate is a novel phosphate binding agent for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis • Second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury • The FDA has granted UNI-494 orphan drug designation for the prevention of Delayed Graft Function in kidney transplant patients • A Phase 1 dose-ranging safety study of UNI-494 in healthy volunteers has been completed Read the full release: https://ir.unicycive.com/news/detail/125/unicycive-therapeutics-to-present-at-the-h-c-wainwright Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive's lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive's second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. For more information, please visit Unicycive.com and follow us on LinkedIn and X. Discover more Featured Companies, Featured Experts, and upcoming Featured Conferences at b2idigital.com. David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted UNCY stock, in line with B2i Digital's practice of investing alongside its Featured Companies. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. See the complete Disclosure at https://b2idigital.com/disclaimer.#stocks #investing #stocktok
0.91% ERengagement of this clip — below the author's average (1.24%)
top 30%outperforms 70% of the author's clips
106%of the author's average views
